Clinical Intelligence

Gintuit receives FDA approval for gum tissue regeneration

Thursday, March 15, 2012 06:00 AM

The FDA has approved Gintuit, a cell-based topical product that has been shown to predictably generate new and aesthetically appealing oral soft tissue, according to Organogenesis.

More... »

Creabilis begins phase IIb trial of CT327 in psoriasis

Wednesday, March 14, 2012 09:25 AM

Creabilis, a European biotechnology company specializing in dermatology, inflammation and pain, has initiated a phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris.

More... »

Tranzyme, Norgine report endpoint failure for ulimorelin

Wednesday, March 14, 2012 09:24 AM

Tranzyme Pharma and Norgine BV, a European specialty pharmaceutical company, reported ULISES 007’s failure to meet its primary and secondary efficacy endpoints.

More... »

HemaQuest raises $13 million for phase IIb study of sickle cell disease

Monday, March 12, 2012 03:49 PM

HemaQuest Pharmaceuticals, a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, has closed a $13 million extension of its Series B financing.

More... »

Genticel completes recruitment for phase Ib HPV vaccine trial

Wednesday, March 7, 2012 06:15 AM

Genticel, a biopharmaceutical company based in Toulouse and Paris, France, has completed the recruitment of all patients participating in its phase Ib clinical trial evaluating a lyophilized formulation of ProCervix, its candidate therapeutic HPV vaccine, on adult women already infected with human papillomavirus (HPV) genotypes 16 or 18.

More... »

NinePoint Medical initiates trial of imaging system for esophagus

Tuesday, March 6, 2012 06:10 AM

NinePoint Medical, a developer of medical devices for in vivo pathology, has initiated a clinical trial to evaluate high-resolution optical imaging of Barrett’s esophagus using its proprietary Nvision VLE Imaging System, which received 510(k) clearance from the FDA earlier this year.

More... »

OncoGenex reports promising preclinical cancer data

Monday, March 5, 2012 06:09 AM

OncoGenex Pharmaceuticals’ compound OGX-427 shows potential for augmenting anti-cancer therapies and delay tumor progression.

More... »

Three studies show positive results in overactive bladder

Friday, March 2, 2012 06:06 AM

Astellas Pharma Europe, subsidiary of Tokyo-based Astellas Pharma, has reported results from three separate clinical trials that further support the efficacy and tolerability of mirabegron for overactive bladder (OAB).

More... »

Nektar releases positive proof-of-concept data for opioid molecule NKTR-181

Thursday, March 1, 2012 06:02 AM

Nektar Therapeutics has reported positive clinical data for NKTR-181, its new oral opioid analgesic molecule.

More... »

Oncolytics Biotech launches phase II study in prostate cancer

Tuesday, February 28, 2012 06:08 AM

Calgary, Cananda-based Oncolytics Biotech has collaborated with the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, to conduct a randomized phase II study of Reolysin in patients with recurrent or metastatic castration resistant prostate cancer.

More... »